bosentan anhydrous has been researched along with Cold Fingers, Hereditary in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Sulli, A | 1 |
| Autenrieth, J; Bert, C; Riemekasten, G; Worm, M | 1 |
| Bruzzone, M; Centanaro Di Vittorio, C; Fusaro, E; Laganà, A; Parisi, S; Peroni, CL | 1 |
| Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; De Paulis, A; Guiducci, S; Lepri, G; Matucci-Cerinic, M; Radicati, A | 1 |
| Cannarile, F; Cestelli, V; Ferri, C; Giuggioli, D; Manfredi, A; Praino, E; Sebastiani, M | 1 |
| Funauchi, M; Hino, S; Kinoshita, K; Kishimoto, K; Nagare, Y; Shimazu, H; Yano, T | 1 |
| Bootsma, H; Hettema, ME; Kallenberg, CG; Smit, AJ; Stienstra, Y; Zhang, D | 1 |
| Denton, CP; Matucci-Cerinic, M; Pope, JE; Steen, V | 1 |
| Wimmersberger, Y; Zuercher, D | 1 |
| Eisendle, K; Gruber, I; Hugl, B; Nguyen, VA; Reider, D; Reider, N | 1 |
| Levien, TL | 1 |
| Borghese, F; Molinaro, I; Pisarri, S; Rosato, E; Rossi, C; Salsano, F | 1 |
| Botzoris, V; Drosos, AA | 1 |
| Bakx, R; Dogan, K; Klemm, PL | 1 |
| Aihara, K; Akaike, M; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S | 1 |
| Kurgyis, Z; Lang, MU; Ruzicka, T; Sárdy, M; Sick, I; Varga, R | 1 |
| Hoffmann, U; Kuhn, A; Riemekasten, G; Sunderkötter, C; Weiss, N | 1 |
| Stern, PJ; Wall, LB | 1 |
| Nishibu, A; Oyama, N; Sakai, E; Yamamoto, T | 1 |
| Brito-Zerón, P; Claver, G; Fernandez, S; Font, J; Julià, M; Nardi, N; Parraga, FD; Ramos-Casals, M; Risco, G | 1 |
| Dunne, J; Dutz, J; Ng, B; Shojania, K; van Eeden, S | 1 |
| Boullanger, N; Carpentier, P; Diot, E; Fain, O; Hachulla, E; Hatron, PY; Jego, P; Launay, D; Mouthon, L; Pasquier, E | 1 |
| Ciurea, A; Distler, J; Distler, M; Distler, O; Kyburz, D; Müller-Ladner, U; Reich, K | 1 |
| Duschek, N; Karlhofer, F; Minimair, G; Selenko-Gebauer, N; Stingl, G | 1 |
| Herrick, AL; Moore, TL; Vail, A | 1 |
| Bootsma, H; Hettema, ME; Kallenberg, CG; Zhang, D | 1 |
| Bergstrom, KG; Perelman, RO | 1 |
5 review(s) available for bosentan anhydrous and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Digital ulcers: overt vascular disease in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Databases, Factual; Endothelium, Vascular; Fingers; Hand Dermatoses; Humans; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2009 |
Advances in the treatment of Raynaud's phenomenon.
Topics: Antioxidants; Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Endothelin Receptor Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iloprost; Phosphodiesterase 5 Inhibitors; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulfonamides; Vasodilator Agents | 2010 |
Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Topics: Bosentan; Calcium Channel Blockers; Cardiovascular Agents; Endothelin Receptor Antagonists; Enzyme Inhibitors; Fingers; Humans; Phosphodiesterase 5 Inhibitors; Prostaglandins I; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2011 |
[Management of digital ulcers in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Ischemia; Male; Raynaud Disease; Risk Factors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2012 |
[Evidence-based therapy of Raynaud's syndrome].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Angiotensin II Type 1 Receptor Blockers; Bosentan; Calcium Channel Blockers; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelin Receptor Antagonists; Epoprostenol; Evidence-Based Medicine; Humans; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Vasodilator Agents | 2006 |
8 trial(s) available for bosentan anhydrous and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Female; Fingers; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin; Skin Temperature; Sulfonamides; Treatment Outcome | 2013 |
Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
Topics: Adult; Aged; Bosentan; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Prospective Studies; Raynaud Disease; Sulfonamides; Treatment Outcome | 2014 |
Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Topics: Adult; Aged; Antihypertensive Agents; Arteries; Bosentan; Connective Tissue Diseases; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Mixed Connective Tissue Disease; Prospective Studies; Pulmonary Artery; Raynaud Disease; Scleroderma, Systemic; Skin Diseases; Sulfonamides; Ulcer; Vasculitis | 2009 |
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Immunosuppressive Agents; Laser-Doppler Flowmetry; Male; Microcirculation; Microscopic Angioscopy; Middle Aged; Nails; Outpatients; Pilot Projects; Raynaud Disease; Regional Blood Flow; Scleroderma, Limited; Sulfonamides; Treatment Outcome; Vasodilation | 2009 |
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Endothelin Receptor Antagonists; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2010 |
Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Laser-Doppler Flowmetry; Male; Middle Aged; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Skin; Sulfonamides | 2010 |
Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2006 |
Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Topics: Adult; Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Male; Microcirculation; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2007 |
14 other study(ies) available for bosentan anhydrous and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis.
Topics: Bosentan; Female; Fingers; Humans; Iloprost; Lasers; Methotrexate; Microcirculation; Microscopic Angioscopy; Middle Aged; para-Aminobenzoates; Raynaud Disease; Scattering, Radiation; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tramadol; Treatment Outcome | 2017 |
Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
Topics: Adult; Aged; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2017 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves Disease; Humans; Hypertension, Pulmonary; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Proteinuria; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2009 |
[A complication of coronary angiography in a female patient with systemic sclerosis].
Topics: Aged; Antihypertensive Agents; Arterial Occlusive Diseases; Bosentan; Coronary Angiography; Female; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2011 |
Bosentan improves systemic sclerosis-related peripheral circulation insufficiency.
Topics: Adult; Aged; Blood Circulation; Bosentan; Female; Humans; Middle Aged; Pain Measurement; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2011 |
Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Female; Hand Dermatoses; Humans; Keratosis; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2011 |
Nonoperative treatment of digital ischemia in systemic sclerosis.
Topics: Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Education, Medical, Continuing; Endothelin Receptor Antagonists; Evidence-Based Medicine; Female; Fingers; Humans; Iloprost; Ischemia; Life Style; Middle Aged; Orthopedics; Phosphodiesterase 5 Inhibitors; Prostaglandins; Randomized Controlled Trials as Topic; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2012 |
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2012 |
Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Topics: Adult; Bosentan; Female; Humans; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2004 |
Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.
Topics: Adult; Bosentan; Female; Fingers; Gangrene; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2006 |
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
Topics: Adult; Aged; Antibodies, Antinuclear; Bosentan; Endothelin-1; Female; Fingers; Follow-Up Studies; Humans; Ischemia; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2007 |
Treatment for Raynaud's: beyond calcium channel blockers.
Topics: Arginine; Bosentan; Botulinum Toxins; Calcium Channel Blockers; Humans; Piperazines; Prazosin; Purines; Raynaud Disease; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |